ANN ARBOR, Mich., SAN DIEGO, and WASHINGTON, Nov. 1, 2010 /PRNewswire/ -- Rubicon Genomics today reported data demonstrating that its PicoPlex™ kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS). The new PicoPlex-NGS WGA (whole genome amplification) and PicoPlex-NGS WMA (whole methylome amplification) kits are designed to produce highly sensitive and reproducible genomic and epigenomic data for cancer, stem cell and embryology applications. Data on Rubicon's new kits were highlighted during the initial lecture at the Single Cell Analysis Summit (SCAS) in San Diego last week and will also be presented at the 2010 American Society of Human Genetics (AHSG) Annual Meeting being held November 2-6, 2010 in Washington DC.
PicoPlex is Rubicon's proprietary method of extracting and amplifying total DNA from single cells and other precious samples—producing relatively large amounts of DNA for genetic and epigenetic profiling analyses in just 3-5 hours. PicoPlex delivers the highest linearity and reproducibility and the lowest background of any commercially-available amplification technology, enabling a wide range of microarray and PCR applications where accuracy and reproducibility are important. Earlier this year, the European Society for Human Reproduction and Embryology reported the success of its "groundbreaking proof of principle study" showing that a new approach incorporating PicoPlex WGA technology could more accurately detect and characterize chromosomal abnormalities in human eggs. The new PicoPlex-NGS WGA and WMA kits are bringing this same level of performance to high throughput sequencing for a wide range of research and diagnostic applications.
"Our PicoPlex kits have been widely adopted for PCR and microarray testing for pre-implantation gene
|SOURCE Rubicon Genomics|
Copyright©2010 PR Newswire.
All rights reserved